Evidence map›Paper›PMID 42698422›Full record

ArticleFrontiers in allergy2026

Incidence rates of allergy diagnoses in the U.S. military health system after the COVID-19 pandemic.

J Joseph Brough, Zella Berill, Apryl Susi, Elizabeth Paloma Sanchez, David Schwartz, Cade M Nylund, Edward Mitre

Abstract read
In one paragraph

Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J Joseph BroughDepartment of Internal Medicine, Walter Reed National Military Medical Center, Bethesda, MD, United States.
Zella BerillHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Apryl SusiHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States.
Elizabeth Paloma SanchezDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
David SchwartzLaboratory of Allergic Diseases, National Institute of Allergy & Infectious Diseases, Bethesda, MD, United States.
Cade M NylundDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: During the COVID-19 pandemic, exposures to environmental allergens and microorganisms were dramatically altered, potentially impacting the development and diagnosis of allergic conditions. Methods: We conducted a retrospective, repeated, monthly cross-sectional study examining monthly incidence rates of allergic diseases diagnosed before and throughout the first 3 years of the COVID-19 pandemic in individuals aged 0-64 years enrolled in the TRICARE Management Activity Military Health System (MHS) Data Repository (MDR). Allergic diseases were grouped into twelve categories. Rates of incident outcomes were calculated monthly and compared between subgroups and during the pre-pandemic year (March 1, 2019-February 29, 2020) and the first 3 years after the COVID-19 Pandemic beginning on March 1, 2020. Results: Allergy diagnoses of all twelve conditions assessed were lower during COVID-19 year 1 (incidence 430 per 100,000) compared with the pre-pandemic year (incidence 750 per 100,000). This reduction in allergic diagnoses during COVID-19 year 1 was statistically significant for all allergic diagnoses queried. During COVID-19 years 2 and 3, allergy diagnoses of all conditions, except for anaphylaxis and food protein induced enterocolitis syndrome (FPIES) remained lower compared with the pre-pandemic year. The decrease in allergic diagnoses was greater than the decrease in total MHS healthcare visits. Discussion: In the MHS, for the first 3 years of the COVID-19 pandemic, allergic diagnoses were lower than in year prior to the pandemic. This reduction cannot be fully explained by decreased healthcare utilization.

Indexed as

allergy diagnosesCOVID-19 pandemichygiene hypothesisinfection—immunologypublic health policy

Identifiers

PMID42698422
PMCPMC13541455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.